The most recent and reliable cancer therapies targeting CCIs are immune checkpoint inhibitors against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) by activating T cells to eliminate tumor cells [4]. This evidence concerns the gene CTLA4 and cancer.